Zhilin Biotech

Zhilin Biotech is an innovative biotechnology company that integrates artificial intelligence (AI) with physics-based modeling to discover next-generation small molecule therapeutics. Founded in 2022 by Dr. Zhilin Li, former head of AI drug discovery at Tencent AI Lab, the company focuses on tackling "undruggable" targets within oncology, immunology, and metabolic disorders. Its proprietary platform leverages high-performance computing and deep learning to optimize drug candidate selection and significantly reduce the traditional timelines of pharmaceutical R&D. Headquartered in Shenzhen with a research facility in Shanghai, the company has secured significant early-stage funding from premier venture capital firms such as Sequoia China. Zhilin Biotech is currently advancing several internal programs through discovery and early pre-clinical development.